# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JP Morgan analyst Lisa Gill maintains Teladoc Health (NYSE:TDOC) with a Neutral and lowers the price target from $16 to $9.
ARKK's high-risk, high-reward strategy has led to a rollercoaster ride with no brakes, while QQQ's safer bet on establi...
Cantor Fitzgerald analyst Sarah James reiterates Teladoc Health (NYSE:TDOC) with a Overweight and maintains $10 price target.
Jim Cramer recommends buying Merck (MRK) due to faith in CEO Robert Davis. He advises against Teladoc (TDOC) due to Cathie Wood...
Piper Sandler analyst Jessica Tassan maintains Teladoc Health (NYSE:TDOC) with a Overweight and lowers the price target from...